# Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs

> **NCT00126945** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 125 (actual)

## Conditions studied

- Infections, Meningococcal

## Interventions

- **BIOLOGICAL:** Meningococcal Vaccine

## Key facts

- **NCT ID:** NCT00126945
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2016-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126945, "Evaluate 4 Different Formulations of Meningococcal Serogroups A,C,W-135,Y Conjugate Vaccine When Given as 1 Dose to Healthy Subjects Aged 15-19 Yrs". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00126945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*